CN104945409A - 一种抗肿瘤活性化合物鬼臼毒素ppt的前药及其制备方法 - Google Patents
一种抗肿瘤活性化合物鬼臼毒素ppt的前药及其制备方法 Download PDFInfo
- Publication number
- CN104945409A CN104945409A CN201510249421.2A CN201510249421A CN104945409A CN 104945409 A CN104945409 A CN 104945409A CN 201510249421 A CN201510249421 A CN 201510249421A CN 104945409 A CN104945409 A CN 104945409A
- Authority
- CN
- China
- Prior art keywords
- ppt
- dcm
- prodrug
- podophyllotoxin
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 title claims abstract description 92
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 title claims abstract description 41
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 229960001237 podophyllotoxin Drugs 0.000 title claims abstract description 39
- 229940002612 prodrug Drugs 0.000 title claims abstract description 37
- 239000000651 prodrug Substances 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 230000000694 effects Effects 0.000 title abstract description 15
- -1 benzopyranyl nitrile amino derivative Chemical class 0.000 claims abstract description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 28
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 20
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 8
- 229910052786 argon Inorganic materials 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 6
- 238000007259 addition reaction Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 150000002148 esters Chemical class 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- KYNFOMQIXZUKRK-UHFFFAOYSA-N 2,2'-dithiodiethanol Chemical compound OCCSSCCO KYNFOMQIXZUKRK-UHFFFAOYSA-N 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 25
- 239000003814 drug Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- YJGVMLPVUAXIQN-HAEOHBJNSA-N picropodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-HAEOHBJNSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000479 mitotic spindle apparatus Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010066925 sleep-promoting factor B Proteins 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 108010001535 sulfhydryl oxidase Proteins 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6432—Quenching
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Biodiversity & Conservation Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种抗肿瘤活性化合物鬼臼毒素PPT的前药及其制备方法,将PPT的C环C4的羟基转变为氯甲酸酯,通过该基团与2-羟乙基二硫化物和苯并吡喃腈氨基衍生物DCM-NH2的加成产物DCM-S反应生成GSH敏感的PPT-S-DCM的前药化合物。本发明所得化合物具有离体和在体肿瘤细胞靶向(GSH敏感)选择释放PPT的特性,有临床应用前景,同时可以利用苯并吡喃腈(DCM)的近红外荧光团检测研究PPT前药化合物的释放行为。
Description
技术领域
本发明属于前药及其制备领域,特别涉及一种抗肿瘤活性化合物鬼臼毒素PPT的前药及其制备方法。
背景技术
恶性肿瘤是严重危害人类健康的常见慢性非传染性疾病,已经成为引起我国居民死亡的首要原因。化学疗法(化疗)是治疗恶性肿瘤的三大手段之一,是直接利用化学药物抑制癌细胞的增殖、浸润、转移直到最终杀死癌细胞的一种治疗手段。与单纯手术治疗相比,采用手术化疗相结合方案治疗的患者无病生存率已由10-20%提高到60-80%,然而,难溶和毒副作用是目前影响一线化疗药物生物利用度和临床疗效的重要瓶颈。而且由于这两方面缺点,很多抗肿瘤活性显著的潜药化合物不能应用于临床,如鬼臼毒素(Podophyllotoxin,PPT)就是其中的一个典型代表,参见Wang B et al.Proteomic changes induced by podophyllotoxin in humancervical carcinoma HeLa cells.The American journal of Chinese medicine,2013,41(01),第163-175页所述。近年肿瘤生物学和药学工作者提出一系列的解决方案,其中化疗化合物前体药物(prodrug)设计合成的思想就是一个巧妙的方案。前体药物,也称前药、药物前体、前驱药物,是指药物经过化学结构修饰后得到的本身无活性或活性较小、在体内经酶或特殊的生理条件转化释放出活性药物而发挥药效的化合物。化疗前体药物本身没有生物活性或活性很低,经过体内代谢后变为有活性的物质,这一过程的目的在于增加药物的生物利用度,加强靶向性,降低药物的毒性和副作用。
前药理论是解决化疗药物毒副作用的有效措施,其中的关键是寻找可利用的肿瘤和正常细胞的生理差异。研究表明,谷胱甘肽(GSH)是人体内一种非常重要的还原性物质,最为重要的是在人体内,细胞外体液(如血液和其它体液)中GSH浓度是微摩尔级别的(20-40μM),而癌细胞内GSH浓度达到毫摩尔级别(1-10mM),这一特殊的肿瘤微环境对于开发基于GSH敏感的生物前体和载体前体药物有重要的意义,参见Hwang C,et al.Oxidized redox state ofglutathione in the endoplasmic reticulum.Science,1992,257(5076),第1496-1502页所述。二硫键(-S-S-)是一种存在于高活性的化学或生物制剂中的非常有价值的官能团,它还广泛存在于蛋白质、氧化型谷胱甘肽(GSSG)和某些天然药物(如丝裂霉素)中,二硫键可以通过两个巯基氧化形成,在轻度氧化剂(如氧气和血液)和生理pH下是非常稳定的,容易与巯基(如GSH的巯基)发生切断二硫键的反应。在众多的含有疏基的还原性化合物包括半胱氨酸(Cys)和高半胱氨酸(Hey),GSH是细胞内含量最高的含疏基化合物,谷胱甘肽同时以还原型(GSH)和氧化型(GSSG)两种形式存在,并且通过两种存在形式之间的平衡对维持生物系统中的氧化还原平衡以及阻止或修复因氧化性损伤而导致的功能紊乱或细胞调亡起到了重要的作用。
鬼臼毒素(Podophyllotoxin,PPT)是一种具有天然活性的木脂素类(lignans)化合物(化学结构式如图1),来源丰富。鬼臼毒素主要通过阻止微管蛋白聚合形成微管而抑制微管在有丝分裂器中的组装从而破坏纺锤丝的形成,细胞分裂活动阻滞于有丝分裂中期。具有强细胞毒性,至今没有成药。上世纪70年代,以鬼臼毒素为前体半合成的糖苷类衍生物依托泊苷(Etoposide)和替尼泊苷(Teniposide),是最早应用于临床的两种鬼臼毒素的衍生物。近来研究表明鬼臼毒素对肝癌、宫颈癌等几种癌细胞的抑制活性至少是其衍生物(包括鬼臼苦素、依托泊苷等)的数倍以上,而且有更宽的抑瘤谱。本专利设计合成鬼臼毒素的前药对解决其毒副作用,为其成为高效化疗药物提供可能。
发明内容
本发明所要解决的技术问题是提供一种抗肿瘤活性化合物鬼臼毒素PPT的前药及其制备方法,本发明所得PPT的前药毒副作用小,具有辨别正常细胞和癌细胞的能力,具有专一性;本发明中所应用的DCM与PPT连接与分离后的荧光变化特性,相比较其他仅能定位荧光标记药物,本发明能够实时监测药物的释放位置及释放情况。
本发明的一种抗肿瘤活性化合物鬼臼毒素PPT的前药,所述化学结构式为:
本发明的一种抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,包括:
(1)苯并吡喃腈氨基衍生物DCM-NH2活化,得到DCM-NH2活化产物;
(2)将上述DCM-NH2活化产物与2-羟乙基二硫化物加成反应得到DCM-S;
(3)将上述DCM-S与鬼臼毒素PPT反应生成DCM-S-PPT,即为鬼臼毒素PPT的前药。
所述步骤(1)中苯并吡喃腈氨基衍生物为DCM-NH2。
所述步骤(1)中活化具体为:三光气和DCM-NH2混合后,在室温和氩气保护下,滴加入N,N-二异丙基乙胺DIEA,111℃反应2-3h。
步骤(1)中在DIEA(N,N-二异丙基乙胺)碱性环境下,利用三光气将DCM-NH2上的氨基活化,得到与羟基反应活性非常高的DCM-NH2异氰酸根。
所述N,N-二异丙基乙胺DIEA、三光气、DCM-NH2的摩尔比为10:2:0.6~12:3:0.8。
步骤(2)的加成反应具体为:在氩气条件下,催化剂、DCM-NH2活化产物和2-羟乙基二硫化物溶液混合后,常温搅拌过夜。
所述催化剂为4-二甲氨基吡啶DMAP;2-羟乙基二硫化物溶液的溶剂为四氢呋喃/二氯甲烷THF/DCM溶液。
所述DCM-NH2活化产物和2-羟乙基二硫化物的摩尔比为1:1~1:1.5。
所述步骤(3)中鬼臼毒素PPT为氯甲酸酯化的PPT。
步骤(3)的DCM-S-PPT的合成:是在DMAP与三光气的环境下,先将PPT C4环上的羟基转变成氯甲酸酯,再将氯甲酸酯化的PPT与DCM-S溶于氯仿,在冰浴避光条件下,用DIEA催化生成DCM-S-PPT。
步骤(3)反应具体为:将真空干燥后的4-二甲氨基吡啶DMAP和鬼臼毒素PPT、三光气混合,在冰浴避光条件下加入干燥的氯仿,磁力搅拌至溶液澄清,然后滴加入DCM-S的氯仿溶液,过夜搅拌反应。
所述DMAP、鬼臼毒素PPT、三光气、DCM-S的摩尔比为10:2.5:1:1.5~12:3.5:1.5:2。
本发明将PPT的C环C4的羟基转变为氯甲酸酯,通过该基团与2-羟乙基二硫化物和苯并吡喃腈氨基衍生物DCM-NH2的加成产物DCM-S反应生成GSH敏感的PPT-S-DCM的前药化合物。
本发明利用了正常细胞与癌细胞在GSH浓度上的差异,以及GSH对DCM-S-PPT上二硫键的切割作用,设计并合成了一种GSH敏感的抗肿瘤前药DCM-S-PPT,该化合物能在癌细胞中被GSH切割成具有抗肿瘤活性的PPT单体,发挥抗肿瘤活性(如图2所示)。本发明还巧妙的利用DCM与PPT分离前后的荧光淬灭与激发特征,提供了一种可以监测DCM-S-PPT在细胞水平、动物水平上的切割及释放情况的方法。
有益效果
(1)毒副作用小,具有辨别正常细胞与癌细胞的能力,能够专一性的杀死癌细胞,对正常细胞影响较小;
(2)本发明中所搭载的PPT抗肿瘤活性比市场上常用的其他同类的抗肿瘤药物的活性更强,活性是鬼臼苦素、依托泊苷等药物的数倍,达到抗肿瘤疗效所需剂量更小;
(3)本发明中所应用的DCM与PPT连接与分离后的荧光变化特性,相比较其他仅能定位荧光标记药物,本发明能够实时监测药物的释放位置及释放情况;
(4)本方法由PPT的C环C4的羟基转变为氯甲酸酯,进一步将氯甲酸酯化的PPT经2-羟乙基二硫化物与苯并吡喃腈氨基衍生物DCM-NH2发生加成反应生成GSH敏感的PPT-S-DCM的前药化合物,其生物相容性比PPT有明显改善,该化合物具有离体和在体肿瘤细胞靶向(GSH敏感)选择释放PPT的特性,有临床应用前景,同时可以利用苯并吡喃腈(DCM)的近红外荧光团检测研究PPT前药化合物的释放行为。
附图说明
图1:鬼臼毒素(Podophyllotoxin,PPT)的化学结构式;A-E为编号;
图2:GSH诱导下的DCM-S-PPT切割反应示意图;
图3:DCM-S的合成,(a)DCM-NH2的活化反应;(b)DCM-NH2与2-羟乙基二硫化物反应合成DCM-S;
图4:DCM-S-PPT前药合成与鉴定,(a)DCM-S进一步与PPT反应生成DCM-S-PPT前药;(b)DCM-S-PPT核磁共振氢谱1H NMR(400MHz,CDCl3),其中插图为DCM-S-PPT的化学结构式;(c)DCM-S-PPT核磁共振碳谱13C NMR(100MHz,CDCl3);
图5:DCM-S-PPT的体外GSH响应实验,(a)DCM-S-PPT在GSH处理前后的紫外-可见吸收谱图及颜色变化(插图);(b)DCM-S-PPT与GSH反应产物的质谱鉴定;
图6:DCM-S-PPT在癌细胞HeLa(a)和SMMC-7721(b)中的显微荧光检测;
图7:DCM-S-PPT在HeLa荷瘤裸鼠中的活体荧光检测,在上肢10mm实体瘤中注射一定剂量的DCM-S-PPT,在小鼠下肢的肌肉内注射相等剂量作为对照,观察注射后1、2、6小时的活体荧光强度。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1
DCM-NH2的活化及DCM-S的合成:
准确称取DCM-NH2(225mg,0.72mmol)和三光气(860mg,2.9mmol),加入到装有35mL干燥的甲苯的100mL三口烧瓶中,在室温和氩气保护下缓慢地逐滴加入DIEA(1.5g,11.7mmol),上述溶液在氩气保护下加热至111℃下进行3h的回流反应,活化反应如图3(a)所示。反应结束后向溶液中鼓吹氩气除掉剩余的光气,氩气环境下加入以THF/DCM溶液为溶剂的2-羟乙基二硫化物(1.2g,90%,7.2mmol),在DMAP催化下,常温下搅拌过夜,加成反应如图3(b)所示。减压旋蒸除掉溶剂,用EA/PE(v/v,1:1)作为洗脱液进行柱层析分离纯化,得到DCM-S红棕色固体96mg,产率为27%。核磁特表征结果如下,1H NMR(400MHz,CDCl3,ppm):δ8.91(d,J=8.4Hz,1H,phenyl-H),7.75(t,1H,phenyl-H),7.61–7.44(m,8H,phenyl-Hand alkene–H),6.85(s,1H,phenyl-H),6.73(d,J=16.0Hz,1H,alkene–H),5.55(s,1H,NH),4.48(t,2H,–O–CH2),3.93(t,2H,OH–CH2),3.02(t,2H,–O–CH2–CH2),2.95(t,2H,–OH–CH2–CH2).13C NMR(100MHz,CDCl3,ppm):δ157.62,152.86,152.33,139.85,138.24,134.63,129.85,129.09,125.96,125.84,118.75,118.58,117.86,117.39,116.87,115.80,106.63,63.35,60.41,41.62,37.52.Mass spectrometry(ESI negative ion mode for[M-H]-):Calcd.for C25H20N3O4S2,490.0895;found,490.0906.说明DCM-S已成功合成。
实施例2
DCM-S-PPT的合成:
称取DMAP(122mg,1.0mmol)于50mL圆底烧瓶中真空干燥15min,然后称取鬼臼毒素(50mg,0.1mmol)和三光气(20mg,0.07mmol)加入圆底烧瓶中,反口塞塞住圆底烧瓶,接着在冰浴避光条件下用注射器加入干燥的氯仿10mL,磁力搅拌至溶液澄清。然后称取苯并吡喃腈衍生物DCM-S(50mg,0.1mmol)溶解于5mL干燥的氯仿中,冰浴下滴入到圆底烧瓶中搅拌至室温,直到溶液变为淡黄色,反应如图4所示。旋干溶剂,柱层析分离(展开剂DCM:EA:PE=1:0.8:1.2),得到土黄色固体10mg,产率为11%。核磁特表征结果如图4(b)和4(c),说明DCM-S-PPT已成功合成。1H NMR(400MHz,CDCl3,ppm):δ=2.91-2.93(m,2H),2.99-3.05(m,4H,-CH2SSCH2-),3.75(s,6H,-OCH3),3.80(s,3H,-OCH3),4.22(t,J=9.2Hz,1H),4.43-4.51(m,6H,-CH2CH2SS CH2CH2-),4.60(d,J=3.6Hz,1H),5.76(d,J=8.4Hz,1H),5.99(s,2H),6.39(t,2H),6.55(s,1H),6.71(d,J=16Hz,1H,alkene-H),6.83(s,1H),6.88(s,1H),7.15(s,1H),7.43-7.58(m,6H,phenyl-H),7.74(t,J=7.6Hz,1H,phenyl-H),8.90(d,J=8.0Hz,1H,phenyl-H).13C NMR(100MHz,CDCl3,ppm):δ=36.99,37.59,38.46,43.73,45.51,56.18,60.76,62.40,62.96,66.24,71.20,101.71,106.60,107.16,108.00,109.74,115.81,116.89,117.35,117.84,118.60,118.74,125.81,125.96,127.47,129.07,129.79,132.44,134.61,134.64,137.11,138.25,139.98,147.72,148.41,152.33,152.66,152.73,152.84,155.36,157.64,173.46.Mass spectrometry(ESI positive ion mode for[M+Na]+):Calcd.for C48H41N3O13S2Na:954.1979;found:954.1979.
实施例3
DCM-S-PPT的体外GSH响应实验:
配置DMSO/PBS=1:1的混合溶剂,取2mL加入到比色皿中,然后加入2μL的DCM-S-PPT(20mM)母液,使其终浓度为10μM,混合均匀后,放入预先调好的37℃水浴锅中,然后加入现配的还原型GSH(0.1M),37℃反应1h后,如图5(a)所示,能够观察溶液颜色变化,其测紫外-可见吸收谱图也发生红移,证明DCM-S-PPT结构发生变化,二硫键可能被切割。
使用高分辨率质谱(HRMS)分析DCM-S-PPT(10μM)与GSH(200μM)37℃反应1h后的反应液,如图5(b)所示,质谱图中同时出现了荷质比为310.1(DCM-NH2)和413.2(PPT)的分子离子峰,再次证明了GSH上的巯基切断了DCM-S-PPT中的二硫键,进而通过分子内脱掉一个含硫五元环,完整的释放出DCM-NH2和PPT。以上数据都说明DCM-S-PPT与GSH反应后的近红外荧光信号的增强与药物的释放是同步的,可以通过追踪近红外的荧光信号实现药物释放的实时监测。
实施例4
DCM-S-PPT的细胞成像和细胞内切割情况监测:
将DCM-S-PPT(200nM)与HeLa和SMMC-7721细胞分别共同孵育3h后进行激光共聚焦成像,如图6所示,可以看到在两种细胞都表现出了很微弱的红色荧光,这部分荧光可能是癌细胞本身表达的GSH将DCM-S-PPT切断后释放的荧光,然而DCM-S-PPT与两种细胞孵育的同时外源的添加GSH(2.5mM)共同孵育3h后,在两种细胞的细胞质内都表现出强烈的红色荧光,说明外源的GSH在细胞培养环境下可以快速的切断DCM-S-PPT的二硫键使得细胞表现出强烈的荧光,而癌细胞本身的GSH在3h内还不足以切断二硫键释放荧光,进而表明GSH与DCM-S-PPT的响应在细胞培养环境下是完全可以实现的。
实施例5
DCM-S-PPT的动物实验:
选用接种HeLa细胞的荷瘤裸鼠为实验对象,等到实体瘤长到直径10mm,直接通过瘤内注射的方式将DCM-S-PPT(0.5mg/Kg PPT的量)注射入肿瘤部位,并在小鼠下肢的肌肉内注射相等剂量作为对照,然后在注射后不同的时间点进行活体成像,如图7所示,可以看到在注射1h后在肿瘤及肌肉部位都出现了荧光,且肿瘤部位荧光强于肌肉组织中的荧光,注射2h后肿瘤部位的荧光继续增强而肌肉组织的荧光则变弱,且注射后6h肿瘤和肌肉组织中的荧光与2h相比都变弱了,通过图片下面的表格可以更直观的看到这种荧光信号的变化趋势。说明肿瘤部位高浓度的GSH可以较完全的切断DCM-S-PPT中的二硫键而释放出近红外荧光,而肌肉组织中也存在较低浓度的GSH会切断很少的部分二硫键表现出较弱的荧光,且在2h时肿瘤内GSH与DCM-S-PPT的反应完全因此荧光强度达到最大,6h荧光变弱可能是活体组织对荧光分子的吸收及泄漏造成(图7)。此实验表明DCM-S-PPT可以被活体内的GSH尤其是肿瘤部位高浓度的GSH切断释放出荧光和抗癌化合物。
Claims (10)
1.一种抗肿瘤活性化合物鬼臼毒素PPT的前药,其特征在于:所述化学结构式为:
2.一种如权利要求1所述的抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,包括:
(1)苯并吡喃腈氨基衍生物DCM-NH2活化,得到DCM-NH2活化产物;
(2)将上述DCM-NH2活化产物与2-羟乙基二硫化物加成反应得到DCM-S;
(3)将上述DCM-S与鬼臼毒素PPT反应生成DCM-S-PPT,即为鬼臼毒素PPT的前药。
3.根据权利要求2所述的一种抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,其特征在于:所述步骤(1)中活化具体为:三光气和DCM-NH2混合后,在室温条件和氩气保护下,滴加入N,N-二异丙基乙胺DIEA,111℃反应2-3h。
4.根据权利要求3所述的一种抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,其特征在于:所述N,N-二异丙基乙胺DIEA、三光气、DCM-NH2的摩尔比为10:2:0.6~12:3:0.8。
5.根据权利要求2所述的一种抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,其特征在于:步骤(2)的加成反应具体为:在氩气条件下,催化剂、DCM-NH2活化产物和2-羟乙基二硫化物溶液混合后,常温搅拌过夜。
6.根据权利要求5所述的一种抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,其特征在于:所述催化剂为4-二甲氨基吡啶DMAP;2-羟乙基二硫化物溶液的溶剂为四氢呋喃/二氯甲烷THF/DCM溶液。
7.根据权利要求5所述的一种抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,其特征在于:所述DCM-NH2活化产物和2-羟乙基二硫化物的摩尔比为1:1~1:1.5。
8.根据权利要求2所述的一种抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,其特征在于:所述步骤(3)中鬼臼毒素PPT为氯甲酸酯化的PPT。
9.根据权利要求2所述的一种抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,其特征在于:步骤(3)反应具体为:将真空干燥后的4-二甲氨基吡啶DMAP和鬼臼毒素PPT、三光气混合,在冰浴避光条件下加入干燥的氯仿,磁力搅拌至溶液澄清,然后滴加入DCM-S的氯仿溶液,过夜搅拌反应。
10.根据权利要求9所述的一种抗肿瘤活性化合物鬼臼毒素PPT的前药的制备方法,其特征在于:所述4-二甲氨基吡啶DMAP、鬼臼毒素PPT、三光气、DCM-S的摩尔比为10:2.5:1:1.5~12:3.5:1.5:2。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510249421.2A CN104945409A (zh) | 2015-05-15 | 2015-05-15 | 一种抗肿瘤活性化合物鬼臼毒素ppt的前药及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510249421.2A CN104945409A (zh) | 2015-05-15 | 2015-05-15 | 一种抗肿瘤活性化合物鬼臼毒素ppt的前药及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104945409A true CN104945409A (zh) | 2015-09-30 |
Family
ID=54160528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510249421.2A Pending CN104945409A (zh) | 2015-05-15 | 2015-05-15 | 一种抗肿瘤活性化合物鬼臼毒素ppt的前药及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104945409A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105670334A (zh) * | 2016-02-29 | 2016-06-15 | 华东师范大学 | 一种葡萄糖基化近红外染料及其制备方法和应用 |
CN106478576A (zh) * | 2016-09-29 | 2017-03-08 | 华南理工大学 | 一种用于检测羧酸酯酶的荧光探针及其制备方法与应用 |
US10023551B2 (en) | 2015-05-12 | 2018-07-17 | Georgetown University | Glutathione-cleavable prodrug and methods of use thereof |
CN112062797A (zh) * | 2020-08-19 | 2020-12-11 | 华南理工大学 | 一种二聚体前药及其制备方法和应用 |
CN114437098A (zh) * | 2020-10-30 | 2022-05-06 | 南京碳硅人工智能生物医药技术研究院有限公司 | 一种近红外荧光标记的gsh响应型的鬼臼毒素前药的设计与合成 |
CN116120333A (zh) * | 2023-02-17 | 2023-05-16 | 沈阳药科大学 | 一种鬼臼毒素纳米前药及其制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1699369A (zh) * | 2005-04-28 | 2005-11-23 | 兰州大学 | 一种鬼臼脂素类化合物及其应用与制备方法 |
WO2010020663A1 (en) * | 2008-08-19 | 2010-02-25 | Pierre Fabre Medicament | New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents |
CN101817829A (zh) * | 2010-04-02 | 2010-09-01 | 浙江大学 | 4-取代苯胺基表鬼臼毒素衍生物及用途 |
-
2015
- 2015-05-15 CN CN201510249421.2A patent/CN104945409A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1699369A (zh) * | 2005-04-28 | 2005-11-23 | 兰州大学 | 一种鬼臼脂素类化合物及其应用与制备方法 |
WO2010020663A1 (en) * | 2008-08-19 | 2010-02-25 | Pierre Fabre Medicament | New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents |
CN101817829A (zh) * | 2010-04-02 | 2010-09-01 | 浙江大学 | 4-取代苯胺基表鬼臼毒素衍生物及用途 |
Non-Patent Citations (2)
Title |
---|
XUMENG WU 等: "In Vivo and in Situ Tracking Cancer Chemotherapy by Highly Photostable NIR Fluorescent Theranostic Prodrug", 《J. AM. CHEM. SOC.》 * |
周明国: "《中国植物病害化学防治研究(第五卷)》", 31 July 2006 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10023551B2 (en) | 2015-05-12 | 2018-07-17 | Georgetown University | Glutathione-cleavable prodrug and methods of use thereof |
CN105670334A (zh) * | 2016-02-29 | 2016-06-15 | 华东师范大学 | 一种葡萄糖基化近红外染料及其制备方法和应用 |
CN105670334B (zh) * | 2016-02-29 | 2017-10-10 | 华东师范大学 | 一种葡萄糖基化近红外染料及其制备方法和应用 |
CN106478576A (zh) * | 2016-09-29 | 2017-03-08 | 华南理工大学 | 一种用于检测羧酸酯酶的荧光探针及其制备方法与应用 |
CN106478576B (zh) * | 2016-09-29 | 2019-01-18 | 华南理工大学 | 一种用于检测羧酸酯酶的荧光探针及其制备方法与应用 |
CN112062797A (zh) * | 2020-08-19 | 2020-12-11 | 华南理工大学 | 一种二聚体前药及其制备方法和应用 |
CN112062797B (zh) * | 2020-08-19 | 2021-09-21 | 华南理工大学 | 一种二聚体前药及其制备方法和应用 |
CN114437098A (zh) * | 2020-10-30 | 2022-05-06 | 南京碳硅人工智能生物医药技术研究院有限公司 | 一种近红外荧光标记的gsh响应型的鬼臼毒素前药的设计与合成 |
CN116120333A (zh) * | 2023-02-17 | 2023-05-16 | 沈阳药科大学 | 一种鬼臼毒素纳米前药及其制备方法与应用 |
CN116120333B (zh) * | 2023-02-17 | 2024-01-26 | 沈阳药科大学 | 一种鬼臼毒素纳米前药及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104945409A (zh) | 一种抗肿瘤活性化合物鬼臼毒素ppt的前药及其制备方法 | |
CN105585571B (zh) | 一种周边单取代的酞菁锌配合物及其阿霉素偶联物 | |
CN105407911A (zh) | 用于癌症靶向治疗和诊断成像的包含基于修饰的血红蛋白的治疗剂的药物组合物 | |
CN108066770A (zh) | 还原响应释放原药的两亲性聚合物药物前体及其制备方法 | |
CN111135299A (zh) | 光敏剂-低氧激活前药一体化前药自组装纳米粒的构建 | |
CN105669831B (zh) | 一类具有光疗和化疗协同抗癌效应的酞菁锌阿霉素偶联物 | |
CN107118249A (zh) | 18β‑甘草次酸衍生物及其应用 | |
Gong et al. | Rational designed highly sensitive NQO1-activated near-infrared fluorescent probe combined with NQO1 substrates in vivo: An innovative strategy for NQO1-overexpressing cancer theranostics | |
CN102258788A (zh) | 一种靶向传递阿霉素抗癌药的组装体及其制备方法 | |
CN109942630B (zh) | 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途 | |
CN113354712B (zh) | 一种酶靶向控制分子内缩合分子探针及其制备方法和应用 | |
CN107216283B (zh) | 一种含有二氢吡啶结构的β-榄香烯衍生物及其制备方法和用途 | |
CN110357899A (zh) | 一类可示踪抗肿瘤鬼臼毒素衍生物及其制备和应用 | |
CN110251685A (zh) | 紫杉醇-黄连素纳米药物的合成方法与应用 | |
CN112279862B (zh) | 近红外卟啉化合物及其制备方法和用途 | |
CN106748939B (zh) | 一类新型溴酚氨基硫脲类化合物及其制备和药物与用途 | |
CN102020598A (zh) | 一种紫草萘醌衍生物及其制备方法和药物的应用 | |
CN101328159B (zh) | 紫杉烷前体抗癌药及其药物组合物和用途 | |
CN102731442A (zh) | 一种水溶性多烯紫杉醇化合物的制备方法及用途 | |
CN102702140B (zh) | 一种水溶性紫杉醇化合物的制备方法及用途 | |
CN103183722B (zh) | 一种乙二醛酶i抑制剂及其制备方法和医药用途 | |
CN102115483B (zh) | 卤代双去氧糖衍生物及其制备方法与应用 | |
CN107955153A (zh) | 一种聚乙二醇-去氧胆酸及其衍生物的制备方法和应用 | |
CN110314238A (zh) | 一种肿瘤靶向的多肽药物偶联物及其制备方法和应用 | |
CN102786458B (zh) | 吡咯甲酰胺衍生物、其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150930 |
|
RJ01 | Rejection of invention patent application after publication |